Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
Hélène Salmon(Immunité et Cancer), Miriam Mérad(Icahn School of Medicine at Mount Sinai), Joshua Brody(New York University), Adeeb Rahman(Immunai (United States)), María Casanova-Acebes(Spanish National Cancer Research Centre), Stefan Jordan(University of California, Santa Cruz), Daigo Hashimoto(Hokkaido University), Brandon Hogstad(Icahn School of Medicine at Mount Sinai), Christina G. Rivera(Icahn School of Medicine at Mount Sinai), Florent Ginhoux(SingHealth), Nina Bhardwaj(Mount Sinai Hospital), Navpreet Tung(Icahn School of Medicine at Mount Sinai), A. Karolina Palucka(Jackson Laboratory), Marylène Leboeuf(Icahn School of Medicine at Mount Sinai), Brian D. Brown(Icahn School of Medicine at Mount Sinai), Svetoslav Chakarov(Ruijin Hospital), Juliana Idoyaga(Rockefeller University), Marcus Bosenberg(Yale Cancer Center), Sacha Gnjatic(Tisch Hospital), Judith Agudo(Dana-Farber Cancer Institute), Romain Remark(Memorial Sloan Kettering Cancer Center), Makhzuna N. Khudoynazarova(Icahn School of Medicine at Mount Sinai)
Cited by 1,165
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
Immunology of COVID-19: Current State of the Science
|Immunity|2020|1.8k